The metabolism of apolipoproteins B-48 and B-100 (apo B-48 and B-100) in large triglyceride-rich lipoproteins (300 to 1500 i in diameter) has been compared in three normal subjects and two subjects with genetically determined deficiency of lipoprotein lipase. The triglyceride-rich lipoproteins were obtained from a lipoprotein lipase-deficient donor 4 hr after a fat-rich meal in order to obtain chylomicrons (containing apo B-48) and very low density lipoproteins (VLDL) (containing apo B-100), whose properties had not been modified by the action of this enzyme. The triglyceride-rich lipoproteins were labeled with 1251 and injected intravenously into recipients who had fasted overnight. In normal recipients, most of the apo B-48 was removed from the blood within 15 min, and most of the apo B-100 was removed within 30 min. In the lipoprotein lipase-deficient recipients, most of the injected apo B-100 remained in the blood for more than 8 hr; removal of apo B-48 was only slightly more rapid. In all subjects, only trace amounts of either protein were found in lipoproteins more dense than 1.006 g/ml. The results indicate that (') the removal of the apo B of both chylomicrons and large VLDL from the blood is dependent upon the hydrolysis of their component triglycerides by lipoprotein lipase, and (it) little or no apo B-48 of chylomicrons or apo B-100 of large VLDL is converted appreciably to low density lipoproteins (LDL). Our results suggest that the reported variability of the conversion of VLDL to LDL may be related to the size and composition of the particles secreted from the liver. The rapid production of remnant particles that are removed efficiently by the liver may minimize the opportunity for further reactions leading to the formation of LDL.
trace amounts of either protein were found in lipoproteins more dense than 1.006 g/ml. The results indicate that (') the removal of the apo B of both chylomicrons and large VLDL from the blood is dependent upon the hydrolysis of their component triglycerides by lipoprotein lipase, and (it) little or no apo B-48 of chylomicrons or apo B-100 of large VLDL is converted appreciably to low density lipoproteins (LDL). Our results suggest that the reported variability of the conversion of VLDL to LDL may be related to the size and composition of the particles secreted from the liver. The rapid production of remnant particles that are removed efficiently by the liver may minimize the opportunity for further reactions leading to the formation of LDL. Apolipoprotein B (apo B) is thought to be essential for the secretion of triglyceride (TG)-rich lipoproteins from the intestine and liver (1) . Recent research has shown that the apo B secreted from the intestine differs from that secreted by the liver of most mammalian species (2) . Although the two proteins are closely related immunologically, the intestinal protein (B-48) has a lower apparent molecular weight and a distinct primary structure from the hepatogenous protein (B-100). In the rat, apo B-48 in intestinal chylomicrons is rapidly removed from the blood by the liver, and essentially none is converted to lipoproteins of higher density (3) . By contrast, a variable fraction of apo B-100, secreted from the liver in very low density lipoproteins (VLDL), is converted to lipoproteins of higher density designated low density lipoproteins (LDL), which are removed much more slowly from the blood (1) . In humans, most of the apo B-100 of VLDL is thought to be converted normally to LDL (1) . However, the fraction so converted appears to be reduced in persons with elevated VLDL levels (4) .
The fate of apo B-48 of chylomicrons in humans has not been determined. In the present research, we 
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in accordance with 18 U.S.C. §1734 solely to indicate this fact. isolation from the donor. The amounts of TG and protein injected into each recipient were 28-58 mg and 1.4-5.6 mg, respectively. To measure lipoprotein composition, TGs (7), free and esterified cholesterol (8) , phospholipids (9), and protein (10) were estimated. Molecular species of apo B were separated in polyacrylamide gels containing NaDodSO4 as described (11) with the modifications described below. The percentage of total 1251 in apo B-100 and apo B-48 varied from 3.3 to 8.3 and from 2.7 to 5.6, respectively. Lipid labeling was 39-55%, and 5-7% was soluble in 1o trichloracetic acid. Fractions of the TG-rich lipoproteins were separated by gel permeation chromatography (12) . Electron microscopy was performed on samples negatively stained with potassium phosphotungstate (13) , and particle diameters were measured on the photographic prints (14) .
Separation of Lipoprotein Fractions. After injection of the TG-rich lipoproteins, the recipients were given fat-free meals for the next 24 hr. Blood was collected at intervals into EDTA. Lipoproteins were immediately separated by sequential ultracentrifugation of 12 ml of plasma in 40.3 rotors of Beckman ultracentrifuges at nonprotein solvent densities of 1.006, 1.019, and 1.063 g/ml (15) . Densities were adjusted to 1.019 g/ml with 2H20 in 0.15 M NaCl and with KBr to 1.063 g/ml. Top fractions were collected in a volume of 3.0 ml. KBr was removed by dialysis against 0.15 M NaCl.
Measurement of Radioactivity. Apo B-100 and B-48 were isolated by electrophoresis in NaDodSO4/polyacrylamide gels as described (11) , with the fbllowing modifications. Cylindrical acrylamide gradient gels (2.5-27%, Isophore electrophoresis gels; Isolab, Akron, OH) were used instead of 3% gels. These gels provided narrower bands, and up to 400 ,g of VLDL protein or 200 ,ug of LDL protein could be applied. Gels were prerun with 0.1 M phosphate tank buffer containing 0.1% NaDodSO4 for 30 min. Portions of the lipoprotein fractions (100-200 ,ul) were applied directly to the gel after additions of NaDodSO4 and sucrose (final concentrations each, 3%). Electrophoresis was performed in the presence of reducing agents (1% mercaptoacetic acid and 1% mercaptopropanediol) for 16 hr at 2 mA. The gels were removed, fixed, and stained in methanol/acetic acid/water, 3:1:6 (vol/vol), containing 0.0025% Coomassie blue for 2 hr at room temperature and 2 hr at 60°C. The gels were destained overnight at room temperature in the same solution without dye. The mobilities of molecular species of apo B were identified with human LDL for B-100 and with rat mesenteric lymph for B-48 (11) . Gels were sliced into 7-9 segments, and radioactivity in each segment was measured in a gamma spectrometer. Recovery of radioactivity in VLDL added to the gels was 75-82% in the normal subjects and 60-67% in the subjects with LPLase deficiency. Recoveries did not vary with time after injection. Correction was made for these systematic losses with the assumption that all components were lost equally. All analyses were performed in triplicate.
The labeled lipoprotein fractions were assayed for unbound iodine by precipitation with 10%o trichloracetic acid in the presence of carrier albumin. (Fig.   1 ). NaDodSO4 electrophoretograms of one labeled preparationi before and after incubation with one recipient's plasma are shown in Fig. 2 for several hours; removal was slow in subject J.C. Removal of 125I-B-100 was slow in both subjects.
In normolipidemic subjects M.B. and S.M., a small amount of radioactivity was found in IDL, but this amount barely exceeded that observed when a portion of the labeled TG-rich lipoproteins was mixed with the recipient's plasma in vitro to give a concentration similar to that occurring immediately after injection in vivo. Only trace amounts (<1%) of 125I-B-100 (and no i25I-B-48) were detected in LDL. In subject W.V., in whom disappearance of 125I-B proteins from the fraction of density < 1.006 g/ml was with a selective deficiency of apo B-100, into whom autologous chylomicrons were injected, except that removal of apo B-48 was somewhat slower (18) . In LPLase-deficient subjects, removal of the protein was markedly delayed, consistent with dependence of the initial step of chylomicron metabolism upon LPLase. A slower removal might result from the expanded size of the chylomicron pool. However, 20 g or more of chylomicron TG normally can be removed from the blood hourly during alimentary lipemia. In the LPLase-deficient subjects, approximately this amount of total TG (chylomicrons plus VLDL) was present in the plasma, but no more than a fraction of this was removed in many hours. Therefore, as in the rat, catabolism of chylomicron TG and apo B-48 in humans evidently proceeds efficiently only when LPLase is active. Also as in the rat, it seems probable that the apo B-48 in chylomicron remnants is rapidly removed and catabolized in the liver. Schaefer et al. (19) have reported that about 15% of total apo B in human thoracic duct lymph chylomicrons is converted to LDL. Presumably, this represented conversion of apo B-100 derived mainly from contaminating hepatic lymph.
By contrast, the metabolism of apo B-100 did not conform to that predicted from published studies in which the entire VLDL fraction of density < 1.006 g/ml has been labeled. Such VLDL are considerably smaller than those that we injected. Furthermore, they contain not only nascent particles but also a variable amount of remnant VLDL that have been partially metabolized by LPL (20) . In normolipidemic humans, such VLDL have residence times of 1-3 hr. By contrast, we observed much shorter residence times for apo B-100 derived from larger VLDL from a subject with LPLasedeficiency, only slightly longer than that observed for apo B-48. The rate of removal of chylomicrons (21) and VLDL (22) is a function of particle size in experimental animals. It has been proposed that the more rapid removal of larger particles reflects association with a larger number of LPLase molecules at the surface of the capillary endothelium (23). Our results suggest that the small differences that we observed in the rate of removal of chylomicrons and VLDL from the blood of normal humans reflect the differing size of the particles injected, rather than an intrinsic difference in susceptibility to the enzyme's action. The slower removal of apo B-100 observed when the entire VLDL fraction is injected then may reflect the smaller size of the average particle. If so, the distribution of circulating VLDL particles does not reflect that of secreted particles. Rather, the smaller secreted particles should predominate in plasma VLDL, together with remnants derived from particles of all sizes.
Recently, Nestel et al. (24) reported on the rates of removal of radioiodinated apo 1B-100 and apo B-48 in TG-rich lipoproteins obtained from patients with severe hypertriglyceridemia not associated with genetically determined LPLasedeficiency. In most cases, the total VLDL fraction was injected, and the size distribution of particles containing the labeled apo B species was not specified. apo B-100 was removed from the VLDL fraction of hypertriglyceridemic recipients more rapidly than was apo B-48. In two normotriglyceridemic subjects, the rates were comparable, but results were expressed as a fraction of the value found 10 min after injection, a time at which a large fraction of the apo B-48 should have left the blood. In view of this difference in experimental design and analysis, comparison with our results is not warranted. They did not measure the conversion of either form of apo B to particles more dense than 1.006 g/ml.
Our results also provide strong evidence that the removal of large nascent VLDL is dependent upon the initial action of LPLase. Removal of apo B-100 in the two enzyme-deficient subjects did not differ appreciably from that of apo B-48. Nicoll and Lewis (25) have reported that the removal of Proc. Natl. Acad Sci. USA 81 (1984) apo B of autologous TG-rich lipoproteins from LPLase-deficient subjects, maintained on a fat-free diet, was impaired little or not at all. This difference may reflect the injection of a population of smaller VLDL than we have used. As suggested by Nicoll and Lewis (25) , the component TGs of small VLDL may be hydrolyzed by hepatic lipase as well as LPLase. Alternatively, these particles might be recognized by the hepatic LDL receptor without preceding lipolysis. The current results are consistent with our earlier observation of grossly impaired catabolism of TG of large VLDL in a LPLase-deficient patient (22) and with the observation that LPLase-deficient patients maintained on low fat diets may develop severe hypertriglyceridemia during pregnancy (1) . During pregnancy, VLDL-TG secretion is thought to be increased, and large VLDL particles may then be produced.
Finally, our results demonstrate that large nascent VLDL may not be converted to LDL at all. This was the case not only in LPLase-deficient subjects but also in normolipidemic ones, in whom remnant particles presumably were formed efficiently. The mechanisms by which LDL are normally produced is unclear. LDL-like particles can be produced from VLDL by the action of LPLase in vitro (26) , but other evidence suggests that the liver participates in the conversion of remnant VLDL to LDL (5, 27) . It has been evident for some time that the conversion of VLDL to LDL must involve more than hydrolysis of VLDL TG and associated transfer of surface components to other lipoproteins, such as high density lipoproteins. VLDL particles, especially those of large size, may contain more molecules of cholesteryl esters than are found in LDL, particularly in hypertriglyceridemic subjects in whom VLDL have long residence times (12) . The larger amount of cholesteryl esters in VLDL of hypertriglyceridemic subjects may result from the continuing process of transfer of these esters from the site of esterification (12) . Our results show that remnant VLDL evidently are not only produced rapidly from such large VLDL but are rapidly cleared from the blood, presumably by LDL receptors in the liver (28 VLDL from humans than the other mammals studied. Several reports suggest that the extent of conversion of VLDL to LDL is reduced in human hypertriglyceridemia (4, 32, 33) . This could reflect the large size of VLDL particles present in some hypertriglyceridemic persons (12) . Furthermore, dependence of conversion upon particle size may explain in part the frequently observed inverse relationship between the concentrations of VLDL and LDL in various disease states and during successful treatment of hypertriglyceridemia (1). In both situations, a crucial determinant of LDL formation may be the size of the nascent VLDL secreted by liver. 
